Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human lymphokine-activated killer cells develop syngeneic killing ability.

G Gallagher1, J Findlay, F A al-Azzawi

  • 1Department of Obstetrics and Gynaecology, University of Cambridge, Addenbrooke's Hospital.

Immunology
|March 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting the outer membrane porin OprF restores carbapenem efficacy during experimental sepsis caused by NDM-1-producing Pseudomonas aeruginosa.

Scientific reports·2026
Same author

Patient-reported outcomes after oesophagectomy in the multicentre LASER study.

The British journal of surgery·2021
Same author

FBXW7 regulates DISC1 stability via the ubiquitin-proteosome system.

Molecular psychiatry·2017
Same author

Major role of pKpQIL-like plasmids in the early dissemination of KPC-type carbapenemases in the UK.

The Journal of antimicrobial chemotherapy·2017
Same author

A Green Journal Initiative.

Veterinary pathology·2017
Same author

Silicone granuloma from ruptured breast implants as a cause of cervical lymphadenopathy.

Annals of the Royal College of Surgeons of England·2016
Same journal

Epidermal Dominance of Metabolically Constrained Immune Niches Underpins Immune Activation Signatures and Clinical Severity in Psoriatic Disease.

Immunology·2026
Same journal

Thymic APC Networks Orchestrate T-Cell Selection: Mechanisms and Therapeutic Opportunities in Immune Disorders.

Immunology·2026
Same journal

Immune Checkpoints in Leukaemia as Gatekeepers of Immuno-Modulation.

Immunology·2026
Same journal

Senescent Human Liver Endothelial Cells Mediate CD4<sup>+</sup> T Cell Recruitment via ICOSL.

Immunology·2026
Same journal

The Transcription Factor EGR2 Plays a Central Role in the Expansion and Function of TCRαβ<sup>+</sup>CD4<sup>-</sup>CD8<sup>-</sup> Double Negative T Cells in lpr Lupus Mice.

Immunology·2026
Same journal

Epigenetic Gene Networks Governing Immune State Transitions Across the Lifespan.

Immunology·2026
See all related articles

Human Lymphokine-Activated Killer (LAK) cells can kill other LAK cells from the same donor, a phenomenon that may impact cancer treatment effectiveness. This syngeneic killing capacity develops over time, influencing LAK cell/IL-2 therapy protocols.

Area of Science:

  • Immunology
  • Cancer Therapy
  • Cell Biology

Background:

  • Lymphokine-activated killer (LAK)-cell therapy shows promise for cancer treatment but has clinical limitations.
  • Understanding LAK cell behavior is crucial for optimizing therapeutic strategies.

Purpose of the Study:

  • To investigate the phenomenon of syngeneic killing among human LAK cells.
  • To assess the development of this killing capacity over time.

Main Methods:

  • Human LAK cells were generated in vitro for varying durations (4 days vs. 8 days).
  • The cytotoxic activity of 'early' LAK cells against 'late' LAK cells, and vice versa, was measured.
  • Syngeneic killing was assessed using LAK cells of different maturation stages (1-4 days difference).

Related Experiment Videos

Main Results:

  • Both 4-day ('early') and 8-day ('late') human LAK cells demonstrated the ability to kill syngeneic LAK cells.
  • Strong cytotoxic activity was observed in both effector-target cell combinations.
  • The capacity for syngeneic killing by human LAK cells was found to be significant and develops with maturation.

Conclusions:

  • Human LAK cells possess a notable capacity for syngeneic killing.
  • This phenomenon has potential implications for the clinical efficacy and administration of LAK cell/IL-2 therapy.
  • Further research is needed to understand and potentially leverage this self-killing behavior in cancer treatment.